HomeGeneticsConditionCLN11 disease
Back to Condition
CLN11 disease
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

CLN11 Disease

CLN11 disease is a rare genetic disorder affecting the nervous system, characterized by adolescent- or early adult-onset seizures, progressive vision loss, and cognitive decline.

Overview

CLN11 disease is a disorder that primarily affects the nervous system, with signs and symptoms typically emerging in adolescence or early adulthood. It is characterized by recurrent seizures, vision loss, coordination problems, and a decline in intellectual function.

CLN11 disease belongs to a group of disorders known as neuronal ceroid lipofuscinoses (NCLs). All NCLs affect the nervous system and cause progressive problems with vision, movement, and thinking. The different types are distinguished by their genetic cause and are designated by "CLN" (ceroid lipofuscinosis, neuronal) followed by a subtype number.

Frequency

The prevalence of CLN11 disease is unknown. At least 11 cases have been described in the scientific literature.

Symptoms

The symptoms of CLN11 disease worsen over time and affect multiple neurological and physical functions:

  • Epilepsy: Recurrent seizures that often involve a loss of consciousness, muscle stiffness (rigidity), and generalized convulsions (tonic-clonic seizures).
  • Vision Loss: Gradual vision loss caused by retinitis pigmentosa (the breakdown of the light-sensitive layer at the back of the eye). Affected individuals may also develop clouding of the eye lenses (cataracts) and rapid, involuntary eye movements (nystagmus).
  • Movement and Speech Issues: Muscle twitches (myoclonus), walking problems and falling (gait disturbance), and impaired speech (dysarthria).
  • Cognitive and Behavioral Changes: Short-term memory loss, loss of executive function (the ability to plan and implement problem-solving strategies), irritability, and impulsivity.
  • Hallucinations: Some individuals experience visual hallucinations involving people or animals.

Causes & Genetic Factors

CLN11 disease is caused by mutations in the GRN gene, which provides instructions for making a protein called progranulin. Progranulin is active in many body tissues, where it helps control cell growth, division, and survival. While its exact function in the brain is not fully understood, progranulin appears to play an important role in the survival of nerve cells.

Mutations causing CLN11 disease result in a complete loss of functional progranulin protein. This deficiency leads to the death of nerve cells in the brain, though the exact mechanism remains unknown. The widespread loss of neurons causes the onset of symptoms in adolescence or early adulthood.

Inheritance

CLN11 disease is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Having mutations in both copies of the GRN gene completely eliminates the production of functional progranulin protein.

The parents of an individual with CLN11 disease each carry one copy of the mutated GRN gene and typically produce about half the normal amount of progranulin. These carriers generally do not show signs of CLN11 disease, but they may develop a different condition called GRN-related frontotemporal lobar degeneration, which causes cognitive decline beginning between a person's forties and sixties. Some individuals with two GRN mutations that still allow for the production of some functional progranulin also develop GRN-related frontotemporal lobar degeneration.

Other Names for This Condition

  • Ceroid lipofuscinosis, neuronal, 11
  • GRN-related neuronal ceroid-lipofuscinosis

Frequently Asked Questions

Clinicians should perform a dilated fundus examination to look for retinitis pigmentosa, which involves the breakdown of the light-sensitive layer at the back of the eye. In CLN11 disease, this is often accompanied by cataracts (clouding of the eye lenses) and nystagmus (rapid, involuntary eye movements). While retinitis pigmentosa can occur in other conditions, the combination of these specific ocular changes with new-onset seizures and cognitive decline in an adolescent is highly suggestive of CLN11 disease. Genetic testing for mutations in the GRN gene is required for a definitive diagnosis. How does the progression of cognitive and behavioral symptoms in CLN11 disease typically unfold, and what are the early warning signs for families?::Early warning signs often include a noticeable decline in academic performance, short-term memory loss, and changes in personality such as increased irritability or impulsivity. As the disease progresses, individuals may lose executive function, which is the ability to plan and solve problems. Some patients also experience visual hallucinations involving people or animals. Families should be alert to these subtle behavioral changes alongside any new seizure activity, as they often precede more severe motor issues like gait disturbances and speech impairment. Is there a specific genetic test for CLN11 disease, and what are the implications for family members?::Yes, CLN11 disease is caused by mutations in the GRN gene. Genetic testing can confirm the diagnosis by identifying pathogenic variants in this gene. Because the condition is inherited, genetic counseling is recommended for affected individuals and their family members. Siblings and parents may be at risk or carriers, and testing can help determine the inheritance pattern and guide future family planning decisions. Early identification through genetic testing is crucial for monitoring and managing symptoms. What is the typical life expectancy and long-term prognosis for individuals diagnosed with CLN11 disease?::The prognosis for CLN11 disease is generally poor, as it is a progressive neurodegenerative disorder. Symptoms such as seizures, vision loss, and cognitive decline worsen over time. While specific life expectancy data is limited due to the rarity of the condition (with only a small number of cases described in literature), the progressive nature of the neuronal ceroid lipofuscinoses (NCLs) group suggests a significant impact on quality of life and longevity. Management focuses on symptom control, such as anti-seizure medications and supportive care, rather than a cure.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss